Major Depressive Disorder Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Major Depressive Disorder remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 1,478 matched trial records and 796 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07703722 | Psilocybin | Phase 3; Recruiting | Khyber Medical University | Pakistan | Depression Severity (Baseline, Week 4, Week 8, and Week 12); Trauma-Related Symptoms (Baseline, Week 4, Week 8, and Week 12) | 2027-10-22 |
| ChiCTR2600127943 | Intervention not normalized | Not Applicable; Not yet recruiting | Huzhou Third Municipal Hospital | China | Medication adherence (Baseline, 3-month of intervention, and 1-month follow-up); Medication Literacy Assessment Scale for patients with mental disorders in recovery (Baseline, 3-month of intervention, and 1-month follow-up) | 2027-04-30 |
| NCT07696871 | Cannabidiol | Phase 1/2; Recruiting | Universidade Do Sul De Santa Catarina | Brazil | Change in Depressive Symptom Severity Assessed by the Hamilton Depression Rating Scale (HAM-17) (Baseline, Week 4, and Week 12) | 2026-12-31 |
| ChiCTR2600127896 | Intervention not normalized | Not Applicable; Not yet recruiting | Sponsor not listed | China | Hamilton Depression Rating Scale | 2027-12-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study) (Phase 3): the indexed record reports Change From Baseline to Day 28 in MADRS Total Score(Least Squares Mean) = -13.9 Scores on a scale (MADRS10) (Standard Error, 1.01); Change From Baseline to Day 28 in MADRS Total Score(Least Squares Mean) = -14.81 Scores on a scale (MADRS10) (Standard Error, 1.00); -.
- A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT) (Phase 3): the indexed record reports Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score(Mean) = -13.4 Scores on a scale (MADRS10) (Standard Deviation, 9.55); Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score(Mean) = -16.8 Scores on a scale (MADRS10) (Standard Deviation, 7.62); -.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants (Phase 2): the indexed record reports Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score(Least Squares Mean) = -8.70 units on a scale (Standard Error, 1.55); Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score(Least Squares Mean) = -11.66 units on a scale (Standard Error, 1.50); Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score(Least Squares Mean): Least square (LS) mean difference = -2.96(95% CI, -7.01 to 1.09), P-Value = 0.15.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Psilocybin (Approved; 5-HT1A receptor x 5-HT2A receptor x 5-HT2C receptor x 5-HT6 receptor), Cannabidiol (Approved). Company & Deal Intelligence records identify sponsor context for Khyber Medical University, Huzhou Third Municipal Hospital, Universidade Do Sul De Santa Catarina. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Major Depressive Disorder has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
